FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 353:2101-2104 November 17, 2005 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Goldie, S. J. PubMed Citation

Cytologic screening has significantly reduced the rates of cervical cancer in many developed countries. However, cervical cancer remains a leading form of cancer among women living in low-resource regions of the world (see map) and often kills women at young ages, when they are still raising families. In these same regions, programs to prevent cervical cancer are unavailable or underfunded because they compete with many other priorities.

View larger version (26K): [in this window] [in a new window]   Incidence of Cervical Cancer Worldwide. Numbers indicate cases per 100,000 population. Data are from the International Association of Cancer Registries, GLOBOCAN 2002.

 
The current standard of cervical-cancer prevention requires three clinical visits: . . . [Full Text of this Article]

Source Information

Dr. Schiffman is a senior investigator and Dr. Castle an investigator at the Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Md.

This article has been cited by other articles:

• Castle, P. E, Scarinci, I. (2009). Should HPV vaccine be given to men?. BMJ 339: b4127-b4127 [Full Text]  
• Duncan, K. J., Eckert, K. A., Clawson, G. A. (2009). Mechanisms of Growth Inhibition in Human Papillomavirus Positive and Negative Cervical Cancer Cells by the Chloromethyl Ketone Protease Inhibitor, Succinyl-Alanine-Alanine-Proline-Phenylalanine Chloromethyl Ketone. J. Pharmacol. Exp. Ther. 330: 359-366 [Abstract] [Full Text]  
• Schiffman, M., Wacholder, S. (2009). From India to the World -- A Better Way to Prevent Cervical Cancer. NEJM 360: 1453-1455 [Full Text]  
• Peng, B., Hu, Q., Liu, X., Wang, L., Chang, Q., Li, J., Tang, J., Wang, N., Wang, Y. (2009). Duchesnea Phenolic Fraction Inhibits In Vitro and In Vivo Growth of Cervical Cancer Through Induction of Apoptosis and Cell Cycle Arrest. Exp. Biol. Med. 234: 74-83 [Abstract] [Full Text]  
• Wang-Johanning, F., Radvanyi, L., Rycaj, K., Plummer, J. B., Yan, P., Sastry, K. J., Piyathilake, C. J., Hunt, K. K., Johanning, G. L. (2008). Human Endogenous Retrovirus K Triggers an Antigen-Specific Immune Response in Breast Cancer Patients. Cancer Res. 68: 5869-5877 [Abstract] [Full Text]  
• Bao, Y P, Li, N, Smith, J S, Qiao, Y L (2008). Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 19: 106-111 [Abstract] [Full Text]  
• Runowicz, C. D. (2007). Molecular Screening for Cervical Cancer -- Time to Give up Pap Tests?. NEJM 357: 1650-1653 [Full Text]  
• Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A. C., Solomon, D., Bratti, M. C., Schiller, J. T., Gonzalez, P., Dubin, G., Porras, C., Jimenez, S. E., Lowy, D. R., for the Costa Rican HPV Vaccine Trial Group, (2007). Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial. JAMA 298: 743-753 [Abstract] [Full Text]  
• Chan, J. K., Berek, J. S. (2007). Impact of the Human Papilloma Vaccine on Cervical Cancer. JCO 25: 2975-2982 [Abstract] [Full Text]  
• Saslow, D., Castle, P. E., Cox, J. T., Davey, D. D., Einstein, M. H., Ferris, D. G., Goldie, S. J., Harper, D. M., Kinney, W., Moscicki, A.-B., Noller, K. L., Wheeler, C. M., Ades, T., Andrews, K. S., Doroshenk, M. K., Kahn, K. G., Schmidt, C., Shafey, O., Smith, R. A., Partridge, E. E., (for The Gynecologic Cancer Advisory Group), , Garcia, F. (2007). American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA Cancer J Clin 57: 7-28 [Abstract] [Full Text]  
• Schmiedeskamp, M. R, Kockler, D. R (2006). Human Papillomavirus Vaccines. The Annals of Pharmacotherapy 40: 1344-1352 [Abstract] [Full Text]  
• Lo, B. (2006). HPV vaccine and adolescents' sexual activity.. BMJ 332: 1106-1107 [Full Text]  
• Kamangar, F., Dores, G. M., Anderson, W. F. (2006). Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. JCO 24: 2137-2150 [Abstract] [Full Text]  
• Steinbrook, R. (2006). The potential of human papillomavirus vaccines.. NEJM 354: 1109-1112 [Full Text]  
• Schiffman, M., Castle, P. E (2006). When to test women for human papillomavirus. BMJ 332: 61-62 [Full Text]